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Thalidomide is a drug that is well known for its teratogenic properties in humans. Surprisingly,
thalidomide does not have teratogenic effects on mouse development. We investigated the effect of
thalidomide on patterning in hydra, an early metazoan with a very simple axial symmetry. Hydra
develops asexually via Wnt-dependent organizer formation, leading to the budding of a new organism.
We observe both induction and inhibition of organizer formation depending on cellular context.
Interestingly, thalidomide treatment altered budding and the developing organizer, but had little effect
on the adult. Expression of Hybra1, a marker of the organizer increased upon thalidomide treatment.
However when the organizer is induced by ectopic activation of Wnt signaling via GSK3 inhibition,
thalidomide suppresses induction. We show that inhibition of Wnt signaling is not mediated by
induction of the BMP pathway. We show that thalidomide activity on organizer formation in hydra
depends on the activity of casein kinase1 and the abundance of β-catenin. Finally, we ﬁnd that interstitial
cells, multipotent cells which give rise to nemoatocytes, neural, digestive and germline cells, are partially
responsible for the inhibitory effect of thalidomide.
& 2013 Elsevier Inc. All rights reserved.Introduction
Thalidomide was initially developed in the 1950s as a sedative
and as a treatment for morning sickness. Tragedy struck when
it turned out that the medical trials performed on mice were
not sufﬁcient and the drug had a devastating teratogenic effect
in humans. Administered during ﬁrst trimester of pregnancy
thalidomide caused severe birth defects, limb malformations
and microtia. Later experiments in chicken and rabbit embryos
revealed a strong teratogenic effect of the drug. This emphasized
the necessity for more extensive clinical trials and suggested the
involvement of thalidomide in multiple molecular mechanisms
(Knobloch et al., 2007; Parman et al., 1999). Later the anti-
proliferative, anti-angiogenic and immunomodulatory properties
of thalidomide and its analogs were found to be very effective in
treatment of multiple myeloma and these drugs became a routine
treatment for this condition. Over the following years different
models of thalidomide teratogenicity have been proposed that
involved activation of BMP and inhibition of Wnt and Fgf pathways
(Hansen et al., 2002; Knobloch et al., 2008), inhibition of angio-
genesis (Therapontos et al., 2009) and oxidative stress (Parmanll rights reserved.et al., 1999). Recently cereblon has been identiﬁed as a molecular
target of thalidomide. Cereblon, a subunit of the E3 ubiquitin
ligase complex, is responsible for the teratogenic effects of
thalidomide and antimyeloma activity of its analogs (Ito et al.,
2010; Zhu et al., 2011). The teratogenic activity of thalidomide was
attributed to the inactivation of the E3 ubiquitin ligase complex
followed by the accumulation of substrate proteins (Ito et al.,
2010). However, those experiments still do not explain the lack
of teratogenic effect of thalidomide in mice indicating that
the response to thalidomide can be species-speciﬁc and tissue-
speciﬁc.
Here we analyze the effect of thalidomide on patterning
processes in hydra. Hydra, a cnidarian, has a very simple body
plan. It consists of a tube (body column) with a head at the apical
end and a foot at the basal end (Fig. 1A) (for review see Bode,
2009). The head is simply an opening of the body column
surrounded by tentacles that catch the prey. The head, body
column and foot are composed of two epithelial layers, the
ectoderm and endoderm (Kanaev, 1969). The epithelial cells of
the body column are constantly dividing and displaced apically in
the upper half and basally in the lower half. When tissue reaches
the apical and basal ends, they undergo head- and foot-speciﬁc
differentiation and are eventually sloughed. This feature of hydra
biology makes it unique in that the pattern formation process is
constantly active. The canonical Wnt pathway operates in the
hypostome, the most apical part of the head, and is responsible for
Fig. 1. Thalidomide induces budding and expression of Hybra1 in the budding zone. (A) Hydra body plan. Dotted arrows indicate the directions of cell displacement.
Expression of Hybra1 in control (B) and treated with 5 μM thalidomide for 6 days hydra (C). Arrowhead indicates ectopic spots of Hybra1 at presumptive head region of the
bud. (D) Animals (15–20/sample) were incubated with 1–200 μM thalidomide, fed during incubation, and the number of new buds was scored on days 4–5. (E) Expression of
Hybra1 in the budding area induced by treatment with 5 μM thalidomide.
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sion of a stable form of β-catenin in hydra results in the formation
of multiple axes (Gee et al., 2010). Tissue of the hypostome that
express components of the canonical Wnt pathway, has organizing
properties and can induce outgrowth of an ectopic axis upon
transplantation into the body column of a host animal (Browne,
1909). In addition to the two epithelial cell lineages there is a third
lineage, the interstitial cell lineage. The interstitial cells (I-cells) are
multipotent stem cells that are located among the epithelial cells
and differentiate into four types of cells: nematocytes, gland and
mucous cells (digestive cells), gametes and nerve cells (for review
see Bode, 1996). The role of I-cells in axis formation in hydra is not
clear. Hydra is capable of maintaining its body plan in the context
of its tissue dynamics and undergo asexual reproduction (bud
formation) without I-cells (Campbell, 1976). However, gland cells
appear to be necessary for the head regeneration process (Guder
et al., 2006).
Here we demonstrate that thalidomide can have opposing
effects on Wnt signaling and pattern formation in hydra, and that
the outcome of thalidomide treatment depends on the cellular
environment. This leads to an alternative molecular model for
thalidomide action that is speciﬁc for hydra, but might be consi-
dered in other model organisms as well. Our work shows that
casein kinase 1 is a regulator of organizer formation in hydra. We
also provide additional evidence for a negative role of interstitial
cells in the induction of the organizer in hydra.Results
Thalidomide both induces and inhibits formation of the organizer in
Hydra.
To determine the effect of thalidomide (Thal) on patterning
processes in hydra we examined three situations in which the
hydra organizer is set up, and subsequently the head is formed.
These are bud formation, head regeneration and induction of
ectopic organizers by alsterpaullone.
Bud formation is the asexual form of hydra reproduction.
It starts as an evagination in the lower half of the body column,
which develops into a cylindrical protrusion with a young hypos-
tome and tentacle bumps at the apical end. A few days later it
forms a foot at the basal end and detaches from the parent as a
small polyp. Incubation of hydra with 1–200 μM thalidomide did
not result in any changes in the hydra body plan except for some
shortening of the tentacles (Fig. 1B and C). However, the budding
rate increased (Fig. 1D). Hybra1, the hydra homolog of Brachyury,
is normally expressed exclusively in the hydra organizer region,
which is located in the adult hypostome and in the apical tip of a
developing bud (Technau and Bode, 1999). Randomly selected
animals were incubated either with 5 μM thalidomide or in control
media for 28 h and analyzed for Hybra1 expression in the budding
zone. Animals were fed at the very beginning of the treatment to
stimulate budding. The number of animals with Hybra1 positive
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treated with thalidomide (Fig. 1E) indicating that thalidomide
induces expression of Hybra1 in the budding zone and stimulates
budding. In addition, ectopic spots of Hybra1 expression are seen
in the presumptive head region of buds developing in the presence
of thalidomide (Figs. 1C and 3D). Buds that developed in the
presence of thalidomide had shorter tentacles and body columns
than did developing buds in control animals. They also failed to
develop a foot and to detach from the parent (data not shown).Fig. 2. Effect of thalidomide on head regeneration. Hybra1 expression during head rege
presence of 100 μM thalidomide (B) 24 h after bisection. (C) Animals (10 animals/sample
head regenerating ends were scored 24, 48 and 72 h after bisection. (D) Animals were
transplanted in the middle of the body column of host animals as described earlier (Br
Fig. 3. Thalidomide blocks inductive effect of alsterpaullone on Hybra1 expression, form
in control media (A,E), with 5 μM Alst (B,F), 5 μM Alstþ100 μM Thal (C,G), 100 μM Thal
monitor the development of tentacles. In (I) pieces of body column of animals trea
transplanted into the middle of body columns of host untreated animals as described
expression.Once back in thalidomide-free media the developmental process
was normal. Although thalidomide induced Hybra1 expression
in the budding zone and in the developing hypostome area,
expression of the gene in the adult hypostome was not affected
(Fig. 1B and C).
Hydra bisected at any level along the body column will
inevitably regenerate a head at the apical end of the lower part,
and a foot at the basal and of the upper part. We bisected hydra in
the middle of the body column and allowed them to regenerate.neration (arrowheads) in the control (A) animals and animals regenerating in the
) were bisected in the middle of the body column, the numbers of tentacles at the
bisected in the middle of the body column, after 48 h head regenerating tips were
oun and Bode, 2002).
ation of ectopic tentacles and ectopic organizer formation. Animals were incubated
(D,H) for 48 h, either ﬁxed for in situ (A–D) or transferred to a drug-free media to
ted with either alsterpaullone or alsterpaullone and thalidomide for 48 h were
earlier (Broun and Bode, 2002). In (D) arrowhead indicates ectopic spot of Hybra1
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of the hypostome speciﬁc gene Hybra1 at the regenerating tip and
the appearance of the tentacles. The induction of Hybra1 expres-
sion was not affected by thalidomide (Fig. 2A and B). However, the
appearance of tentacles in the regenerating head was delayed in
the animals regenerating in the presence of thalidomide (Fig. 2C).
In adult hydra the organizer capacity, which is deﬁned by its
ability to induce a second axis in the host tissue upon transplanta-
tion, is an exclusive property of the hypostome. The tissue of
a body column lacks this ability (Browne, 1909). During head
regeneration this organizer capacity gradually accumulates in the
tip of the regenerating head (Broun and Bode, 2002). To test if
thalidomide affects this accumulation we transplanted regenerat-
ing tips into the middle of the body column of host animals.
Regenerating tips isolated from thalidomide-treated animals
induced a 2nd axis at the same rate as did regenerating tips from
controls (Fig. 2D). However, these 2nd axes had a reduced number
and size of tentacles in the developing head. Thus, thalidomide
does not affect organizer formation during head regeneration as
evidenced by Hybra1 expression and transplantation experiments,
but does inhibit tentacle morphogenesis.
The canonical Wnt pathway is active in the hydra hypostome
and is responsible for setting up and maintaining the organizer in
that location (Hobmayer et al., 2000). Expression of a stable form
of β-catenin throughout the animal results in the formation of
multiple axes along the body column (Gee et al., 2010). Ectopic
activation of the canonical Wnt pathway in the body column
by inhibiting the activity of GSK3-β with alsterpaullone (Alst)
leads to the accumulation of organizing capacity throughout the
body column. This capacity, which is normally restricted to theFig. 4. Inhibitory effect of thalidomide realizes neither through the activity of existing o
regenerating halves of hydra after 48 h of incubation in the control media (A), with 5 μ
Hybra1 in the foot area often seen in animals treated with thalidomide. Expression of Hyhypostome, is reﬂected in the induction of the hypostome speciﬁc
gene Hybra1 all over the body column (Broun et al., 2005; Fig. 3A
and B). After removal of alsterpaullone, the animal develops
tentacles all over the body column (Fig. 3F). Simultaneous treat-
ment with alsterpaulone and thalidomide completely blocked
induction of Hybra1 in the body column and the development of
ectopic tentacles (Fig. 3C and G). Thalidomide had this inhibitory
effect in a wide range of concentrations from 1 to 200 μM (data not
shown). The accumulation of inductive capacity was abolished as
well. Transplants taken from the body column of the animals that
received the simultaneous treatment failed to induce a 2nd axis in
a host, while transplants from the animals treated with alster-
paullone alone induced 2nd axes in 100% of treated animals
(Fig. 3I). Interestingly, while blocking ectopic expression of Hybra1
and the accumulation of organizer capacity in the body column,
thalidomide did not inhibit the endogenous expression of Hybra1
in the head (Fig. 3D) or the inductive activity of the hypostome
(data not shown).
Thus, thalidomide blocks the induction of ectopic organizers in
hydra, but has no effect when organizer is formed at its natural
locations during budding and head regeneration.
Inhibitory effect of thalidomide does not depend on the organizer
activity of a hypostome
The organizer in the hypostome maintains the hydra body plan
by producing and transmitting two signals, the head activator
and the head inhibitor, to the body column (Meinhardt, 1993).
The head activator is involved in maintaining the organizer, while
the head inhibitor diffuses down the body column and preventsrganizer not through activation of BMP pathway. Expression of Hybra1 in the lower
M Alst (B) and with 5μM Alstþ50 μM Thal. Arrowhead (C) indicates expression of
DKK 1/2/4-C in control animals (D) and animals treated with 5 μM Thal for 48 h (E).
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Their molecular nature still remains unknown, although head
activation is most likely directly linked to the canonical Wnt
signaling (Broun et al., 2005; Gee et al., 2010), and gap junctions
are required to pass the inhibitory signal down the body column
(Fraser et al., 1987). This raised the possibility that the inhibitory
effect of thalidomide on alsterpaullone-induced formation of an
organizer is due to an increase in head inhibition secreted by the
hypostome. To examine this possibility, hydra bisected in the
middle of the body column was incubated with the drugs for 48 h.
Alsterpaullone induced expression of ectopic Hybra1 throughout
the lower regenerating half (Fig. 4B). Strikingly, thalidomide
blocked this induction (Fig. 4C) resulting in an expression pattern
similar to that in an untreated control (Fig. 4A). Expression of
Hybra1 at the regenerating tip was not affected by thalidomide.
(Fig. 4C). Thus, the inhibitory effect of thalidomide on alsterpaullone-
induced formation of an ectopic organizer in the body column is
unrelated to the activity of the endogenous organizer in the
hypostome.
The BMP pathway is not affected by thalidomide
The Dickkopf proteins are antagonists of Wnt (for review see
Niehrs, 2006). Thalidomide upregulates the BMP pathway during
limb development in chick embryos, which leads to the induction
of Dickkopf and the subsequent inhibition of the canonical Wnt
pathway (Knobloch et al., 2007). In hydra the homolog of Dickkopf,
HyDKK 1/2/4-C, is expressed in the gland cells of the endoderm in
the body column (Augustin et al., 2006). The expression patterns
of HyDKK 1/2/4-C and Wnt3 are mutually exclusive, which suggests
HyDKK 1/2/4-C may play a role in the regulation of the canonical
Wnt pathway in hydra (Guder et al., 2006). If expression of HyDKK
1/2/4-C is affected by thalidomide, this would suggest that the
BMP pathway is involved in the inhibition of the alsterpaullone
induction of the canonical Wnt pathway in the body column. It
would also imply that the gland cells are involved in maintaining
axial patterning in hydra.
Expression of HyDKK 1/2/4-C was analyzed by in situ hybridi-
zation in polyps treated with 5 μM thalidomide for 48 h and
compared with controls. The expression of HyDKK 1/2/4-C was
not affected by thalidomide treatment (Fig. 4D and E). A prolongedFig. 5. Upper halves of hydras 4 days after bisection in the control media (A) and in the
tubulin antibody (green) in the control (C), incubated with Thal (D) and with nocodazo
Nuclei are stained with DAPI (blue). Expression of Hybra1 in the controls (F), animals in
(I) and Alstþ10−9 M nocodazoleþThal (J) for 48 h.5 days treatment with thalidomide as well as treatments with
higher concentrations also did not result in changes of HyDKK 1/2/
4-C expression (results not shown). We conclude that in hydra
thalidomide does not affect the BMP pathway as it does during
limb development in chick embryos. Thus, it is likely that inhibi-
tion of alsterpaullone-induced Wnt pathway is mediated by a
different mechanism.
The molecular mechanisms underlying the inhibitory effect of
thalidomide do not involve polymerization of microtubules
It has recently been shown that an uneven distribution of
β-catenin between daughter cells during early divisions in C. elegans
embryos followed by activation of Wnt signaling is directly linked to
microtubule polymerization (Sugioka et al., 2011). Phosphorylation
of tau, a microtubule binding protein, prevents microtubule poly-
merization. Since tau is one of the targets of GSK3-β (for review
see Sun et al., 2009), treatment with alsterpaullone might also
affect microtubule assembly. CDK5, another kinase inhibited by
alsterpaullone, also contributes to the regulation of microtubule
polymerization (Flaherty et al., 2000). We wanted to determine
if the inhibitory effect of thalidomide on the activation of Wnt
signaling by alsterpaullone was due to changes in microtubule
polymerization.
Microtubule polymerization plays an essential role in regulat-
ing the length of the hydra body column. Normally after bisecting
a hydra in the middle of the body column, the upper half will
undergo elongation (Takaku et al., 2011). However, disruption of
microtubules with nocodazole prevents this elongation (Takaku
et al., 2011). We observed that hydra regenerating in the presence
of 100 μM of thalidomide failed to elongate their upper regenerat-
ing halves (Fig. 5A and B). Also, the fact that buds developing in
the presence of thalidomide have shorter tentacles and body
columns indicates that thalidomide might affect microtubule
assembly in hydra. Treatment with thalidomide did not change
the abundance of polymerized tubulin as detected by immuno-
histochemistry (Fig. 5C and D) and western blot analysis (data not
shown). Next, we wanted to see if microtubule polymerization
is necessary for the inhibitory effect of thalidomide. Hydra
was treated with alsterpaullone and thalidomide in the presence
of 10−9 M nocodazole. Used in that concentration nocodazolepresence of 100 μM Thal (B). Polymerized tubulin detected with anti – acetylated
le (Noc) (E) animals, in the ectoderm (arrows) and in the endoderm (arrowheads).
cubated with Alst (G), with 10−9 M nocodazole (H), with Alst þ10−9 M nocodazole
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Nocodazole did not affect expression of Hybra1 induced by
alsterpaullone and the inhibition of that induction by thalidomide
(Fig. 5F,G,H,I, and J). Thus, the molecular mechanisms mediating
the inhibitory effect of thalidomide on the Wnt pathway do not
involve polymerization of microtubules.
Interstitial cells mediate the inhibitory effect of thalidomide on
ectopic expression of Hybra1 while not affecting its activating effect.
The anti-proliferative activity of thalidomide and its analogs are
well documented (Moreira et al., 1999; Hideshima et al., 2000).
In order to see if thalidomide has the same effect on hydra cells we
pulse-labeled hydra with BrdU and ﬁxed the tissue immediately
thereafter. About 80–90% of the BrdUþ cells are rapidly dividing
interstitial cells (I-cells), while the rest are slowly dividing epithe-
lial cells (Campbell and David, 1974; David and Campbell, 1972).
Dividing I-cells form nests of 2,4,6,8 and sometimes 16 cells (Lehn,
1951). Treatment with thalidomide did not cause a signiﬁcant
change in the overall number of BrdU positive cells. However,
there was an increase in the fraction of BrdUþ cells located in
nests and an increase in the fraction of big nests containing eight
or more nematoblasts (Table S1, Supplementary material). Treat-
ment with alsterpaullone causes disintegration of nematoblast
nests and early differentiation of I-cells (Khalturin et al., 2007).
When applied along with alsterpaullone, thalidomide prevented
this disintegration (Table S1, Supplementary material). Thus,
thalidomide either stimulates the proliferation of I-cells or inhibits
their terminal differentiation or both.
In order to see if interstitial cells mediate the effects of
thalidomide on patterning and Hybra1 expression we made use
of temperature sensitive sf-1 strain. Exposure of sf-1 animals to
an elevated temperature results in the removal of cells of the
interstitial cell lineage, resulting in an animal that consists only ofFig. 6. Expression of Hybra1 in the normal (epiþ) and ‘epithelial’ animals (epi-) of sf-1 st
5 μM alsterpaullone (B), 5 μM alsterpaullone and 1μM thalidomide (C), 1 μM thalidomidepithelial cells (Sugiyama and Fujisawa, 1978). These ‘epithelial
hydra’ as well as normal animals were treated with thalidomide
and alsterpaullone. As the concentrations of alsterpaullone and
thalidomide used in previous experiments were toxic for ‘epithe-
lial’ animals, they were exposed to reduced concentrations of
0.5 μM for alstrpaullone and 1 μM for thalidomide. These concen-
trations were effective in inducing and repressing Hybra1 expres-
sion in the body column of control sf-1 animals (Fig. 6A, B, and C).
‘Epithelial hydra’ was more sensitive to drug treatments than the
normal hydra resulting in contraction of the body column and loss
of tentacles. Treatment with alsterpaullone induced expression of
Hybra1 in both ‘epithelial' and control animals (Fig. 6B and E).
However, treatment with both alsterpaullone and thalidomide
produced a different result. In control animals thalidomide
strongly inhibited the induction of Hybra1, while in ‘epithelial'
animals this inhibition was partial and Hybra1 was still expressed
along the body column (Fig. 6C and F). This observation suggests,
that cells of the interstitial lineage are responsible for the inhibi-
tory effect of thalidomide in sf-1 animals.
As we have shown, thalidomide does not inhibit an expression
of Hybra1 in the hypostome and at the tip of the bud. In those
locations Wnt signaling is naturally active. These areas are also
devoid of most types of cells of the interstitial cell lineage (Bode
et al., 1973). Were this inductive effect due to the absence of
interstitial cells we should observe activation of Hybra1 in ‘epithe-
lial’ animals upon treatment with thalidomide in the same manner
we observe induction of Hybra1 spots at the tips of developing
buds (Fig. 1C). But we did not observe any ectopic Hybra1 spots
when ‘epithelial’ animals were treated with thalidomide alone
(Fig. 6G). To conﬁrm this result we used another source of
‘epithelial’ animals hydra of the 105 strain depleted of cells of
the interstitial lineage by treatment with colchicine (Campbell,
1976). Treatment with thalidomide alone did not result in ectopic
expression of Hybra1, while alsterpaullone induced Hybra1 all overrain. Normal animals (A–D) and ‘epithelial’ animals (E–G) were treated for 48 h with
e (D,G), 0.5 μM alsterpaullone (E), 0.5 μM alsterpaullone and 1 μM thalidomide (F).
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by thalidomide at the tips of developing buds cannot be explained
by the reduced number of interstitial cells.
Thalidomide induces accumulation of beta-catenin in hydra nuclei
Upon activation of Wnt signaling, β-catenin rescued from
ubiquitinization and subsequent degradation, localizes in the
nucleus and becomes a part of the LEF/TCF transcriptional com-
plex. Nuclear localization of β-catenin in hydra occurs in situations
where Wnt signaling is active: in the hypostome and upon
induction of Wnt signaling by alsterpaullone in the body column
(Broun et al., 2005). We wanted to see if changes in Hybra1
expression upon thalidomide treatment reﬂect changes in the
subcellular localization of β-catenin. We used a transgenic strain of
Hydra vulgaris bearing a copy of the β-catenin gene fused to GFP
(Nakamura et al., 2011). Treatment with alsterpaullone induced
translocation of β-catenin to nuclei along the body column as
expected (Fig. 7B and F). To our surprise treatment with thalido-
mide also induced translocation of β-catenin to nuclei (Fig. 7D
and H), although the intensity of nuclear immunoﬂuorescent
staining was usually lower then when treated with alsterpaullone.
Double treatment with alsterpaullone and thalidomide yielded
the same result (Fig. 7C and G). However, the effects varied among
different animals from a strong accumulation of β-catenin compar-
able to that observed with thalidomide treatment to no β-catenin
accumulation at all (data not shown). The induction of Hybra1
in the body column reﬂected nuclear accumulation of β-catenin.
Alsterpaullone caused strong induction of Hybra1 all over the body
column (Fig. 7L), while thalidomide alone and in combination with
alsterpaullone caused the appearance of Hybra1 spots and occa-
sionally weak expression of Hybra1 along the body column
(Fig. 7M and N). Thus, in transgenic animals that have an extra
copy of β-catenin, both thalidomide and alsterpaullone stimulate
accumulation of β-catenin in nuclei, but thalidomide weakens the
ectopic expression of Hybra1 (Fig. 7M).Fig. 7. Nuclear accumulation of beta-catenin-GFP in hydra body column cells. Transgenic
5 μM alsterpaulloneþ5 μM thalidomide (C,H,M), 5 μM thalidomide (D,I,N), 5 μM thalidom
ﬁxed and proceeded either directly to ﬂuorescent imaging (A–J) or to in situ hybridizatThis differs from the effect of thalidomide on the wild type
strain where thalidomide induces expression of Hybra1 only at the
tip of a bud, but not in the body column of an adult animal
(Fig. 1C). Interestingly, the expression of endogenous β-catenin in
wild type animals is higher in the hypostome, budding zone and in
the developing bud (Hobmayer et al., 2000). Thus, it appears, that
thalidomide induces transcription of Hybra1 in locations with
a higher level of β-catenin transcript. Our results show, that
thalidomide stimulates translocation of β-catenin into nuclei, but
unlike when translocated due to inhibition of GSK-3β upon alster-
paullone treatment, this β-catenin does not induce expression of
Hybra1.
Casein kinase 1 antagonizes the inductive effect of thalidomide on
ectopic expression on Hybra1
Casein kinase I phosphorylates several members of the cano-
nical Wnt pathway and contributes to both activation and inhibi-
tion of the pathway (for review see Price, 2012). Partial sequences
of delta (δ) and epsilon (ε) isoforms of CK1 were identiﬁed in
hydra. Comparison of their kinase domains with kinase domains of
vertebrate CK1 revealed 91% identity for δ and 87% identity for ε
isoforms (Fig S1. Supplementary material). We made use of an
antibody that reacted with the ε and δ isoforms. A high level of
casein kinase 1 was detected in the cytoplasm of big and small
interstitial cells along the hydra body column. The expression level
was lower in other cells (Fig. 8C and D). Because there are no big
I-cells and few small i-cells in the head, the abundance of CK1 in the
hypostome and tentacles and in the presumptive head area of a
developing bud was much lower than in the body column (Fig. 8A
and B). Since the concentration of CK1 has an axially speciﬁc
distribution, we wanted to see if a change in enzyme activity would
affect axial patterning or interfere with the thalidomide effect.
Treatment of hydra with casein kinase inhibitors PF670462 or
IC261 did not result in changes in either axial patterning or Hybra1
expression (Fig. 8E and F) or in the morphology of animals. However,hydra bearing β-catenin-GFPwere treated for 48 h with 5 μM alsterpaullone (B,G,L),
ideþ2 μM PF 670462 (E,J) or left in control media (A,F,K). After 48 h animals were
ion (K–N). Arrowheads indicate accumulation of beta-catenin-GFP in nuclei.
Fig. 8. Casein kinase 1 is involved in patterning process in hydra. Detection of CK1 in hydra ectoderm in an adult hypostome (A), head region of a developing bud (B), and
body column (C,D). CK1 is in abundance in the cytoplasm of big i-cells (arrows) and small i-cells (arrowheads). Expression of Hybra1 (E–J) and induction of ectopic tentacles
(L) in hydra treated with inhibitors of CK1. Animals were treated with 5μM IC261 (E) and 20μM PF67046 (F) along, 1 μM Thalþ5 μM IC261 (I), 1 μM Thalþ0.25 μM PF67046
(G,K), 1 μM Thalþ2.5 μM PF67046 (H,L), 1 μM Thalþ20 μM PF67046 (J) for 48 h and either ﬁxed for in situ (E–J), or kept in a drug free media (K,L). In (G) arrowhead indicates
ectopic Hybra1 spots in the budding area often seen after treatment with thalidomide.
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the expression of Hybra1 was induced in the body column (Fig. 8H,I,
and J). Treatment of hydra with 1 μM thalidomide and 2.5 μM
PF670462 for 48 h resulted in the induction of Hybra1 all over the
body column, accumulation of β-catenin in nuclei (Fig. 8E and J) and
induction of ectopic tentacles along the body column (Fig. 8L). A
lower concentration of 1.5 μM PF670462 was not effective (Fig. 8G
and K). Thus, inhibition of CK1 combined with thalidomide treat-
ment mimics the effect of alsterpaullone: it activates expression of
organizer speciﬁc gene Hybra1 in the body column and induces
formation of ectopic tentacles.
Next we wanted to ﬁnd out the relationship between the
mechanism of induction of ectopic head structures (CK1/thalido-
mide mechanisms) and the mechanism of inhibition of ectopic
head structures (alsterpaullone/thalidomide mechanism). Animals
were incubated either in media containing a mixture of alster-
paullone and thalidomide as described earlier, or in the same
media containing increasing concentrations of PF670462. While
animals treated with the alsterpaullone/thalidomide mixture didnot develop ectopic structures, animals incubated with the same
mix and 0.5 μM PF670462 developed ectopic tentacles (Fig. S2,
Supplementary material). Thus, induction of an organizer in response
to thalidomide and inhibition of CK1 is epistatic to the thalidomide-
induced inhibition of an organizer formation.
The mechanism of suppression of the Wnt pathway by thalidomide in
hydra cannot be mimicked by proteosome inhibition
Recently cereblon (CRBN) has been identiﬁed as a molecular
target of thalidomide. CRBN mediates the teratogenic effect of
thalidomide on limb development in chick embryos (Ito et al.,
2010) as well as anti-oncogenic and proapoptotic effects on multi-
ple myeloma cells (Zhu et al., 2011). Cereblon is a component of E3
ubiquitin ligase complex (Ito et al., 2010). The function of this
complex is to ubiquinate substrate proteins which prepare them for
further proteosomal degradation. In agreement with this data,
treatment with the proteosomal inhibitor MG132 inhibits the Wnt
pathway and mimics thalidomide-induced limb malformations in
Fig. 9. Expression of Hybra1 in the control animals (A) and animals treated for 48 h with 5 μM alsterpaullone (B), 5 μM alsterpaullone and 50 μM MG132 (C), and 50 μM
MG132 (D).
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zomib is used in treatment of multiple myeloma along with
thalidomide and lenalidomide (Katzel et al., 2007; Richardson
et al., 2005). The sequence homologous to cereblon gene is identi-
ﬁed in hydra (Compagen cluster name HAEP_T-CDS_v02_9466)
suggesting that molecular mechanisms of thalidomide-mediated
inhibition of organizer formation may be conserved in hydra.
To determine if the inhibition of proteosomal degradation mimics
the inhibitory effect of thalidomide onWnt pathway in hydra as well,
Hyβcatenin-EGFP hydras were incubated with 10 μM of the proteo-
somal inhibitor MG132. This resulted in the accumulation of
β-catenin in Hyβcatenin-EGFP animals demonstrating that MG132 is
effective in hydra (data not shown). After 48 h of incubation MG132
had no effect on alsterpaullone-induced expression of Hybra1 in wild
type animals (Fig. 9A, B, and C). Incubation with MG132 alone also
did not induce ectopic expression of Hybra1 (Fig. 9D). Thus, inhibition
of proteosome degradation in hydra does not mimic the inhibi-
tory effect of thalidomide on allsterpaullone-induced activation of
Wnt pathway. This result suggests an alternative mechanism for
the thalidomide-induced inhibition of the Wnt pathway in hydra.
Another important conclusion from this experiment is that inhibition
of proteosomal degradation of β-catenin is likely not sufﬁcient for
induction of the Wnt pathway in hydra.Discussion
Thalidomide exhibits teratogenic effect on chick limb develop-
ment by means of suppression of Wnt/β-catenin and subsequent
induction of apoptosis in the apical ectodermal ridge (AER)
(Knobloch et al., 2007). The role of Wnt signaling in anti-
oncogenic and pro-apoptotic effects of thalidomide on multiple
myeloma cells remains unclear. However, components of Wnt
pathway are downregulated in multiple myeloma cell lines in
response to lenalidomide, an analog of thalidomide (Bjorklund
et al., 2011). The same studies showed that multiple myeloma cell
lines resistant to lenalidomide have higher levels of β-catenin
expression and low activities of GSK3β and CK1. In hydra we
observed two effects of thalidomide on the Wnt/β-catenin path-
way. (1) Inhibition of the pathway when it is induced ectopically,
and (2) activation of the pathway when expression of β-catenin is
high as in Hyβcatenin-EGFP hydra and in the budding zone of
a wild type animal. To our knowledge this is the ﬁrst report
demonstrating the activation of the Wnt pathway by thalidomide.In chickens, thalidomide represses the Wnt pathway by acti-
vating the BMP pathway followed by induction of the Wnt
antagonist Dickkopf and inhibition of the Akt pathway (Knobloch
et al., 2007, 2008). Both mechanisms result in the activation of
GSK3β, subsequent induction of apoptosis in the AER and limb
truncation. In hydra expression of HyDkk1, does not change
in response to thalidomide treatment, indicating that the BMP
pathway is, probably, not affected. In chickens thalidomide-
dependent inhibition of Akt is partially due to the stabilization
of the phosphatase PTEN. Stabilization of PTEN with the proteo-
some inhibitor MG132 mimics this effect of thalidomide (Knobloch
et al., 2008). The proteosomal inhibitor bortezomib is used
in treatment of multiple myeloma along with thalidomide and
lenalidomide (Richardson et al., 2005). Our results show that this
is not the case in hydra and inhibition of the alsterpaullone-
induced Wnt pathway is not due to inhibition of proteosome.
The teratogenic effect of thalidomide on limb development in
chickens can be reversed with GSK3β-speciﬁc inhibitors (Knobloch
et al., 2007). In hydra, on the contrary, thalidomide reverses the
effect of GSK3β inhibition on Wnt signaling indicating that the
molecular mechanisms of thalidomide action are located down-
stream of the GSK3β-dependent phosphorylation of β-catenin.
Unlike other organisms, in hydra thalidomide induces the
translocation of β-catenin into nuclei. Expression of a stable form
of β-catenin in hydra results in the ectopic expression of Hybra1 as
well as the induction of the Wnt pathway in the body column (Gee
et al., 2010). Whether or not, the thalidomide-induced nuclear
translocation of β-catenin leads to induction of the Wnt pathway
seems to depend on other factors as well.
First, the fact that ectopic expression of Hybra1 can be induced
by thalidomide in situations when expression of β-catenin is
elevated suggests that the response to thalidomide treatment
depends on the concentration of the β-catenin transcript. It is
possible that the amount of β-catenin translocated into nucleus in
response to thalidomide treatment is simply not sufﬁcient to
initiate the transcription of organizer genes. Recent studies
showed that the repressor region in the HyWnt gene promoter
that normally prevents expression of HyWnt in the body column
can be silenced by an excess of nuclear β-catenin (Nakamura et al.,
2011). Transgenic Hyβcatenin-EGFP hydra have an extra copy of
the β-catenin gene (Nakamura et al., 2011). Cells in the budding
zone of a wild type hydra also have a higher concentration of
the β-catenin transcript than cells in the rest of the body
column (Hobmayer et al., 2000). In those situations the amount
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of organizer genes. This result resembles the effect of an analog
of thalidomide, lenalidomide, on multiple myeloma cells lines.
In drug-resistant lines in which the expression of β-catenin is
elevated, lenalidomide induces expression of the Wnt pathway
(Bjorklund et al., 2011). However, this model cannot explain inhibi-
tion of the ectopic Wnt pathway by thalidomide in alsterpaullone-
treated animals where the β-catenin protein is in excess due to
inhibition of GSK3β. Further studies need to be carried out to
determine the role of the concentration of the β-catenin transcript
on the outcome of thalidomide treatment.
A second factor that affects the outcome of thalidomide
treatment in hydra is the activity of CK1. We have shown that
inhibition of CK1 δ and ε in combination with thalidomide
treatment activates the Wnt pathway (Fig. 8H, I, J, and L). This,
again, resembles the activation of the Wnt pathway by lenalido-
mide in drug-resistant lines of multiple myeloma cells: activation
of the pathway is accompanied by depletion of CK1 (Bjorklund
et al., 2011). In hydra thalidomide on its own stimulates transloca-
tion of β-catenin into nuclei, but β-catenin fails to induce tran-
scription of Hybra1 until CK1 is inhibited. In mammalian cells CK1
δ/ε have three negative effects on Wnt signaling. These includeFig. 10. Schematic model of thalidomide action in cells of hydra body column. (A) con
destruction complex, which leads to the proteosomal degradation of β-catenin; (B) tre
β-catenin is translocated into nucleus along with protein(s)—APC, which prevents
and alsterpaullone; (D) treatment with thalidomide and PF 670462: inhibition of CK1 p
β-catenin/LEF1 transcriptional complex.(1) CK1 δ/ε phosphorylates and activates APC leading to the
recruitment of β-catenin to the APC/Axin/Gsk3β degradation
complex (Choi et al., 2005); (2) CK1 δ/ε phosphorylates β-catenin
priming it for phosphorylation by GSK3β; (3) CK1 δ/ε phos-
phorylates LEF-1, the transcriptional cofactor of β-catenin, thereby
preventing the formation of the LEF-1/β-catenin complex
(Hämmerlein et al., 2005) (for review see Price, 2006). Inhibition
of CK1 alone in hydra is not sufﬁcient for the induction of
Wnt pathway, possibly, due to the high activity of GSK3β. But if
accompanied by thalidomide-induced nuclear export of β-catenin,
inhibition of CK1 δ/ε leads to the activation of the organizer-
speciﬁc gene Hybra1 and induction of ectopic tentacles (Fig. 8J
and L). This result is similar to the inhibition of GSK3β by
alsterpaullone. Further experiments to analyze the distribution of
CK1 activity along the hydra body axis and among different cell
types have to be done in order to clarify the role of CK1 in axis
development in hydra.
How does thalidomide prevent the excess of β-catenin
accumulated upon alsterpaullone treatment from engaging in
transcriptional activity? Thalidomide might affect proteosomal
degradation of β-catenin or the amount of β-catenin transported
into the nucleus, and that this amount is not sufﬁcient to initiatetrol: in the absence of Wnt signaling β-catenin is recruited into APC/Axin/Gsk3β
atment with thalidomide and (C) treatment with thalidomide and alsterpaullone:
β-catenin from forming complex with LEF-1; (C) treatment with thalidomide
revents releases β-catenin from binding to APC and promote the formation of the
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thalidomide does not inhibit endogenous Wnt signaling in the
hypostome. This fact rather suggests that there is/are step(s) in
the process of induction of Wnt pathway that is/are speciﬁc for the
body column, and those steps are affected by thalidomide.
A possible way of exporting β-catenin into nucleus and keeping
it transcriptionally inactive would be the translocation of some
other protein(s) into nucleus that bind to β-catenin and prevent it
from forming a complex with LEF-1. Axin and APC, components
of APC/Axin/Gsk3β destruction complex, could be such proteins
(Fig. 10A,B, and C) (Henderson, 2000). Nuclear APC competes with
LEF-1 for binding to β-catenin leading to the down regulation
of the Wnt pathway (Neufeld et al., 2000; Sierra et al., 2006).
As described above CK1 ε/δ negatively regulates Wnt pathway
through phosphorylation of APC and LEF-1. Thus, inhibition of CK1
ε/δ would promote the formation of the β-catenin/LEF1 transcrip-
tional complex (Fig. 10D). In the hypostome, where the Wnt
pathway is active, an APC/Axin/Gsk3β destruction complex is not
formed and β-catenin is translocated into the nucleus to partici-
pate in transcription. Thus, this model includes both the fact
that CK1 antagonizes the inductive effect of thalidomide on Wnt
signaling, and the fact that thalidomide has different effects on
Wnt signaling in the hypostome and body column of hydra.
As we show here, thalidomide stimulates proliferation and
delays differentiation of interstitial cells in the gastric region as
manifested by an increase in the number of BrdUþ nests as well as
the number of cells in each of those nests. In contrast, treatment
with alsterpaullone promotes early differentiation of nematoblasts
and the dissociation of these nematoblast nests that normally
takes place in the head/organizer region (Khalturin et al., 2007;
Table S1, Supplementary material). This dissociation of nests is
prevented when animals are treated with both thalidomide and
alsterpaullone. At this point we cannot say if this effect of
thalidomide on interstitial cells is primarily due to the inhibition
of alsterpaullone-induced organizer formation or is a consequence
of that. Inhibition of terminal differentiation of interstitial cells
might be the cause for shortening of tentacles, inhibition of foot
formation during bud development and inhibition of tentacle
formation during head regeneration.
The role of interstitial cells in organizer formation in hydra is
somewhat controversial. Removal of cells of the interstitial lineage
relieves the head regeneration defect in the reg-16 mutant of
hydra (Sugiyama and Wanek, 1993). At the same time gland cells,
one of the interstitial lineage derivatives, are required for head
regeneration (Guder et al., 2006). Here we show that cells of the
interstitial lineage are at least partially responsible for the inhibi-
tory effect of thalidomide on alsterpaullone-induced activation of
the organizer-speciﬁc Hybra1 gene. Interestingly, the hydra homo-
log of cereblon, the gene responsible for teratogenic effect of
thalidomide in higher metazoan, is expressed predominantly in
cells of interstitial lineage (see cluster name HAEP_T-CDS_v02_
9466 at Compagen). This fact suggests that in hydra cereblon
might play a similar role in thalidomide-depended inhibition of
alsterpaullone-induced formation of an organizer.
Recently, the BMP pathway has emerged as a potential inhi-
bitor/regulator of organizer formation in hydra. The hydra homo-
log of Dickkopf, a Wnt antagonist induced by the BMP pathway, is
expressed exclusively in gland cells in the body column. The
expression pattern of HyDkk1 is complimentary to that of HyWnt,
which is expressed exclusively in the hypostome (Augustin et al.,
2006; Guder et al., 2006). However, expression of HyDkk1 does
not change after treatment with thalidomide, indicating that the
BMP pathway is, probably, not affected. An intriguing explanation
comes from the fact that inhibition of CK1, abundantly expressed
in interstitial cells, synergizes with thalidomide and induces the
expression of an organizer speciﬁc gene, Hybra1, all over the bodycolumn. Subsequently ectopic tentacles also form all along the
body column (Fig. 10F)—an effect similar to the inhibition of GSK3β
with alsterpaullone. However, interstitial cells clearly are not the
only source of CK1 inhibitory input since treatment of ‘epithelial’
hydra with thalidomide does not lead to ectopic expression of
Hybra1. Thus, in order to induce an organizer in response to
thalidomide, activity of CK1 needs to be reduced in epithelial cells.
Taken together, our work provides the ﬁrst report of a dual
effect of thalidomide on Wnt signaling. This effect is observed in
hydra, a metazoan with a very simple axial symmetry. We show,
that the mechanism of thalidomide action does not involve
the BMP pathway and cannot be mimicked by inhibition of
the proteosome. Casein kinase 1 antagonizes an inductive effect
of thalidomide on Wnt signaling in hydra. The abundance of
β-catenin transcript seems to also play a role in the outcome of
thalidomide treatment. Thus, we suggest an alternative mechan-
ism of thalidomide action, possibly, speciﬁc for hydra.
Our work also brings new data to the understanding of axis
formation in hydra. First, we introduce CK1 as a new player in the
patterning process in hydra. To what extend the activity of CK1
regulates the axis formation in hydra needs to be determined. We
also show that prevention of β-catenin from proteosomal degrada-
tion might not be sufﬁcient to induce the Wnt pathway in hydra.
Finally, we provide additional evidence for the inhibitory role of
interstitial cells in organizer formation in hydra.Material and methods
Animals and culture conditions
Hydra vulgaris AEP and β-catenin-EGFP strains (Nakamura et al.,
2011) and Hydra magnipapillata 105 and sf-1 (Sugiyama and
Fujisawa, 1978) strains were used. Animals were cultured as
described previously at þ18 C (Smith et al., 1999). To eliminate
interstitial cells from animals of sf-1 strain polyps were incubated
at 25 C for 5 days and then kept at 18 C for 2 weeks. Loss of
interstitial cells was monitored by macerate examination (David,
1973). To eliminate interstitial cells from polyps of 105 strain
animals were treated with colchicine as described previously
(Campbell, 1976).
Treatment with drugs and tissue manipulations
Alsterpaullone (Sigma–Aldrich), thalidomide (Sigma–Aldrich),
MG132 (kind gift of Anurag Tandon), PF67046 (kind gift of
Anthony Pawson) and nocodazole (Sigma) were used in concen-
trations described in the text. Unless indicated, animals were
treated for 48 h, rinsed a few times in a drug free media and
incubated further without drugs. Transplantation experiments
were performed as described earlier (Broun and Bode, 2002).
In situ hybridization
In situ hybridization analysis was carried out on whole mounts
of hydra as described previously (Grens et al., 1996). HyDKK
1/2/4-C clone was a kind gift of Thomas Bosch.
Immunocytochemistry on whole mounts
Animals were relaxed in 2% urethane for 2 min, and then ﬁxed
in 4% paraformaldehyde for 2 h at 4 1C. Then, animals were
washed 320 min in PBST (PBS with 0.1% Triton), permeabilized
in PBS with 0.5% Triton, washed 210 min in PBST and incub-
ated in PBST with 2% BSA for 1 h. Incubations with anti-acetylated
tubulin antibody (1:500, Sigma) and anti-CK1 antibody (1:200,
M. Brooun et al. / Developmental Biology 378 (2013) 51–6362Transduction Laboratories) were done at 4 1C O/N. Then, animals
were washed 310 min PBST with 2% BSA, incubated with
secondary antibody ( FITC donkey anti-mouse IgG, 1:400, Jackson
Laboratories) for 90 min, washed with PBST 310 min and
mounted using Vectashield mounting medium containing DAPI
(Vector Laboratories, Inc). Unless indicated, all steps were per-
formed with rotation at RT. For direct visualization of β-catenin-
EGFP in β-catenin-EGFP strain animals were ﬁxed in 4% parafor-
maldehyde O/N at 4 1C, washed 320 min with PSB and mounted
using Vectashield mounting medium containing DAPI. Samples
were examined with confocal microscopy.
Whole mount immunoﬂuorescent BrdU detection
Animals were incubated with 5 mM BrdU (Sigma) for 15 min,
washed with hydra media two times, relaxed in 2% urethane and
ﬁxed with 4% PFA at 4 1C O/N. Fixed animals were washed with
PBS 310 min, treated with 2 N HCl for 40 min and washed again
with PBS 8–10 times for 2 min. Then sample were incubated in PBS
with 0.5% Triton for 30 min, washed 25 min with PBST (PBS
with 0.1% Triton) and incubated in PBST with 2% BSA for 1 h. The
following incubation with mouse anti-BrdU antibody (1:200,
Dako), washes and examination were carried out as described
above.
Phylogenetic analysis
Sequence alignment was performed using Clustal Omega align-
ment tool (http://www.ebi.ac.uk/Tools/msa/clustalo/). Sequences used:
mouse CK1δ (NP_620690.1), zebraﬁsh CK1δ (EU127826.1), mouse
CK1ε (NM_013767.6), zebraﬁsh CK1ε (EU127824.1), hydra sequences
XM_002167598 and CO538525.1.Acknowledgments
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